Print

HVTN 503 (Phambili)

A Multicenter Double-Blind Randomized Placebo-Controlled Phase IIB Test-of-Concept Study to Evaluate the Safety and Efficacy of a Three-Dose Regimen of the Clade B-Based Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in HIV-1 Uninfected Adults in South Africa

Trial Details:

IIb Terminated
National Institute of Allergy and Infectious Diseases (NIAID), Merck, HIV Vaccine Trials Network (HVTN) February 01, 2007
MRKAd5 HIV-1 gag/pol/nef
MRKAd5 HIV-1 gag/pol/nef Viral Vector - Adeno
South Africa 3,000